<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="Original Article In silico screening of FDA approved drugs reveals" exact="ergotamine" post="and dihydroergotamine as potential coronavirus main protease enzyme inhibitors"/>
 <result pre="In silico screening of FDA approved drugs reveals ergotamine and" exact="dihydroergotamine" post="as potential coronavirus main protease enzyme inhibitors GurungArun Bahadurarunbgurung@gmail.comaâ�ŽAliMohammad"/>
 <result pre="for each enzyme target. Interestingly, the anti-migraine drugs such as" exact="ergotamine" post="and its derivative, dihydroergotamine were found to bind to"/>
 <result pre="Interestingly, the anti-migraine drugs such as ergotamine and its derivative," exact="dihydroergotamine" post="were found to bind to all the three target"/>
 <result pre="drug candidates. Keywords Coronaviruses Coronaviral main protease FDA approved drugs" exact="Ergotamine" post="Dihydroergotamine COVID-19 SARS-CoV-2 SARS-CoV MERS-CoV 2019-nCoV 1 Introduction Coronaviruses"/>
 <result pre="candidates. Keywords Coronaviruses Coronaviral main protease FDA approved drugs Ergotamine" exact="Dihydroergotamine" post="COVID-19 SARS-CoV-2 SARS-CoV MERS-CoV 2019-nCoV 1 Introduction Coronaviruses are"/>
 <result pre="The top five lead molecules identified for SARS-CoV-2 Mpro were" exact="Dihydroergotamine" post="(ZINC000003978005), Avodart (ZINC000003932831), Irinotecan (ZINC000001612996), Ergotamine (ZINC000052955754) and Olysio"/>
 <result pre="molecules identified for SARS-CoV-2 Mpro were Dihydroergotamine (ZINC000003978005), Avodart (ZINC000003932831)," exact="Irinotecan" post="(ZINC000001612996), Ergotamine (ZINC000052955754) and Olysio (ZINC000164760756) with binding energies"/>
 <result pre="for SARS-CoV-2 Mpro were Dihydroergotamine (ZINC000003978005), Avodart (ZINC000003932831), Irinotecan (ZINC000001612996)," exact="Ergotamine" post="(ZINC000052955754) and Olysio (ZINC000164760756) with binding energies of âˆ’9.4Â"/>
 <result pre="and âˆ’9.2Â kcal/mol respectively (Table 1). The best lead molecule" exact="Dihydroergotamine" post="(ZINC000003978005) binds to a pocket within the Cys145-His41 dyad"/>
 <result pre="Binding Energy (kcal/mol) Molecular Interactions Hydrogen bonds Hydrophobic interactions ZINC000003978005" exact="Dihydroergotamine" post="âˆ’9.4 O1â€¦..N(Gly143) [3.13Â Ã…]O4â€¦..N(Gly143) [2.80Â Ã…] Thr25, His41, Cys44,"/>
 <result pre="Glu166, Pro168, Arg188, Gln189 and Thr190 (NÂ =Â 10) ZINC000001612996" exact="Irinotecan" post="âˆ’9.3 N4â€¦..O(Thr26) [3.00Â Ã…]O3â€¦..NE2(Gln192) [2.90Â Ã…] Thr24, Thr25, His41,"/>
 <result pre="Met165, Glu166, Pro168, Gln189 and Thr190 (NÂ =Â 13) ZINC000052955754" exact="Ergotamine" post="âˆ’9.3 O4â€¦..N(Gly143) [3.13Â Ã…] Thr25, His41, Cys44, Met49, Asn142,"/>
 <result pre="wireframe representation) and molecular interaction between SARS-CoV-2 Mpro and (A)" exact="Dihydroergotamine" post="(ZINC000003978005) (B) Î±-ketoamide 13b inhibitor (O6K). The hydrophobic interactions"/>
 <result pre="second target-SARS-CoV Mpro, the top 5 lead molecules identified were" exact="Saquinavir" post="(ZINC000026985532), Ergotamine (ZINC000052955754), Nilotinib (ZINC000006716957), Raltegravir (ZINC000013831130) and Dihydroergotamine"/>
 <result pre="Mpro, the top 5 lead molecules identified were Saquinavir (ZINC000026985532)," exact="Ergotamine" post="(ZINC000052955754), Nilotinib (ZINC000006716957), Raltegravir (ZINC000013831130) and Dihydroergotamine (ZINC000003978005) with"/>
 <result pre="top 5 lead molecules identified were Saquinavir (ZINC000026985532), Ergotamine (ZINC000052955754)," exact="Nilotinib" post="(ZINC000006716957), Raltegravir (ZINC000013831130) and Dihydroergotamine (ZINC000003978005) with binding energies"/>
 <result pre="were Saquinavir (ZINC000026985532), Ergotamine (ZINC000052955754), Nilotinib (ZINC000006716957), Raltegravir (ZINC000013831130) and" exact="Dihydroergotamine" post="(ZINC000003978005) with binding energies of âˆ’9.6Â kcal/mol, âˆ’9.5Â kcal/mol,"/>
 <result pre="and âˆ’9.2Â kcal/mol respectively (Table 2). The best lead molecule-" exact="Saquinavir" post="(ZINC000026985532) exhibits four hydrogen bonds (Three bonds with the"/>
 <result pre="Binding Energy (kcal/mol) Molecular Interactions Hydrogen bonds Hydrophobic interactions ZINC000026985532" exact="Saquinavir" post="âˆ’9.6 O6â€¦..N(Glu166) [2.83Â Ã…]N5â€¦..OE1(Gln189) [3.06Â Ã…]O2â€¦..O(Leu141) [2.75Â Ã…]O1â€¦..N(Gly143) [2.89Â"/>
 <result pre="His164, Met165, Leu167, Thr190 and Gln192 (NÂ =Â 12) ZINC000052955754" exact="Ergotamine" post="âˆ’9.5 O1â€¦..N(Gly143)O4â€¦..N(Gly143) Thr25, His41, Met49, Asn142, Cys145, His164, Met165,"/>
 <result pre="Cys145, His164, Met165, Glu166 and Gln189 (NÂ =Â 9) ZINC000006716957" exact="Nilotinib" post="âˆ’9.4 N4â€¦..OD(Asn142) [3.03Â Ã…]N1â€¦..O(His164) [3.15Â Ã…] Thr25, His41, Cys44,"/>
 <result pre="Leu141, Gly143, Asp187, Arg188 and Gln189, (NÂ =Â 10) ZINC000003978005" exact="Dihydroergotamine" post="âˆ’9.2 O4â€¦..N(Ser144) [3.34Â Ã…]O4â€¦..N(Gly143) [2.67Â Ã…]O1â€¦..N(Gly143) [2.98Â Ã…] Thr25,"/>
 <result pre="red wireframe representation) between SARS-CoV Mpro lead compounds and. (A)" exact="Saquinavir" post="(ZINC000026985532) (B) inhibitor SG85 (G85). The hydrophobic interactions are"/>
 <result pre="leads for the third target-MERS-CoV Mpro were found to be" exact="Ergotamine" post="(ZINC000052955754), Ak-Fluor (ZINC000003860453), Avodart (ZINC000003932831), Dihydroergotamine (ZINC000003978005) and Saquinavir"/>
 <result pre="were found to be Ergotamine (ZINC000052955754), Ak-Fluor (ZINC000003860453), Avodart (ZINC000003932831)," exact="Dihydroergotamine" post="(ZINC000003978005) and Saquinavir (ZINC000026664090) with binding energies of âˆ’9.6Â"/>
 <result pre="be Ergotamine (ZINC000052955754), Ak-Fluor (ZINC000003860453), Avodart (ZINC000003932831), Dihydroergotamine (ZINC000003978005) and" exact="Saquinavir" post="(ZINC000026664090) with binding energies of âˆ’9.6Â kcal/mol, âˆ’9.4Â kcal/mol,"/>
 <result pre="and âˆ’8.1Â kcal/mol respectively (Table 3). The best lead molecule-" exact="Ergotamine" post="(ZINC000052955754) binds to a region within the Cys148-His41 catalytic"/>
 <result pre="Binding Energy (kcal/mol) Molecular Interactions Hydrogen bonds Hydrophobic interactions ZINC000052955754" exact="Ergotamine" post="âˆ’9.6 O3â€¦..SG(Cys148) [3.23Â Ã…] Met25, His41, Leu49, Leu144, Cys145,"/>
 <result pre="Met168, Glu169, Asp190, Lys191 and Gln192 (NÂ =Â 10) ZINC000003978005" exact="Dihydroergotamine" post="âˆ’9.3 O1â€¦..SG(Cys145) [3.35Â Ã…] Met25, His41, Leu49, Leu144, Cys148,"/>
 <result pre="Glu169, Asp190, Lys191, Gln192 and His194 (NÂ =Â 11) ZINC000026664090" exact="Saquinavir" post="âˆ’9.3 O2â€¦..SG(Cys145) [3.21Â Ã…]O3â€¦..NE2(His41) [2.97Â Ã…]N3â€¦..OE1(Gln192) [3.13Â Ã…]N5â€¦..OE1 (Gln192)"/>
 <result pre="wireframe representation) between MERS-CoV Mpro and lead compounds and (A)" exact="Ergotamine" post="(ZINC000052955754) (B) inhibitor GC813 (AW4). The hydrophobic interactions are"/>
 <result pre="and green dashed lines correspond to hydrogen bonds. The molecules-" exact="Dihydroergotamine" post="(ZINC000003978005) and Ergotamine (ZINC000052955754) were identified to be common"/>
 <result pre="lines correspond to hydrogen bonds. The molecules- Dihydroergotamine (ZINC000003978005) and" exact="Ergotamine" post="(ZINC000052955754) were identified to be common leads interacting with"/>
 <result pre="the favourable number of hydrogen bonds and hydrophobic interactions. Both" exact="Ergotamine" post="and its derivative, Dihydroergotamine have been used in clinical"/>
 <result pre="hydrogen bonds and hydrophobic interactions. Both Ergotamine and its derivative," exact="Dihydroergotamine" post="have been used in clinical practice for the treatment"/>
 <result pre="of pharmacological binding with several receptors such as 5-HT (5-hydroxytryptamine)," exact="dopamine" post="and noradrenaline receptors and are potent vasoconstrictors (Bigal and"/>
 <result pre="binding with several receptors such as 5-HT (5-hydroxytryptamine), dopamine and" exact="noradrenaline" post="receptors and are potent vasoconstrictors (Bigal and Tepper, 2003,"/>
 <result pre="docking approach. Our study suggests that anti-migraine drugs such as" exact="Ergotamine" post="(ZINC000052955754) and its derivative, Dihydroergotamine (ZINC000003978005) are the most"/>
 <result pre="that anti-migraine drugs such as Ergotamine (ZINC000052955754) and its derivative," exact="Dihydroergotamine" post="(ZINC000003978005) are the most potent lead molecules which can"/>
</results>
